Dermatology Archives - Page 9 of 17

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

Amalia Leceta, Aintzane García, Ander Sologuren, Cristina Campo

Article Type

Review

Published

10 Aug 2021

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino

Article Type

Review

Published

09 Aug 2021

The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Martina Burlando, Riccardo Castelli, Emanuele Cozzani, Aurora Parodi

Article Type

Erratum

Published

20 Jul 2021

The authors wish to make the following corrections to their article: Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs in Context 2021; 10: 2021-2-6. DOI: 10.7573/dic.2021-2-6

Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic

Tiago Torres, Marta Pereira, Maria João Paiva Lopes, Clarisse Rebelo, Pedro Andrade, Martinha Henrique, Hugo Oliveira, Paulo Ferreira, Gabriela Marques Pinto, Francisco Menezes Brandão, Jorge Rozeira, Paulo Filipe, Rui Tavares Bello

Article Type

Original Research

Published

09 Jun 2021

This article describes the real-life strategies and therapeutic options adopted by dermatologists regarding their patients with psoriasis being treated with or with an indication for systemic therapy during the first COVID-19 lockdown period in Portugal.

Bimekizumab: the new drug in the biologics armamentarium for psoriasis

Egídio Freitas, Tiago Torres

Article Type

Editorial

Published

08 Jun 2021

Bimekizumab is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one of the drugs to be observed in 2021. This article discusses the current status of bimekizumab.